Critical analysis of Alzheimer's amyloid-beta toxicity to mitochondria

被引:41
|
作者
Kaminsky, Yury G. [1 ]
Tikhonova, Lyudmila A. [1 ,2 ]
Kosenko, Elena A. [1 ,2 ]
机构
[1] Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Russia
[2] Pushchino State Inst Nat Sci, Pushchino, Russia
来源
FRONTIERS IN BIOSCIENCE-LANDMARK | 2015年 / 20卷
关键词
Amyloid-beta; Alzheimer's disease; Brain regions; Mitochondria; Non-neuronal cells; Toxicity; Review; PERMEABILITY TRANSITION PORE; ADENINE-NUCLEOTIDE TRANSLOCASE; PEPTIDE-INDUCED APOPTOSIS; COMPLEX IV ACTIVITY; A-BETA; OXIDATIVE STRESS; BRAIN MITOCHONDRIA; PRECURSOR PROTEIN; FRAGMENT; 25-35; A-BETA(25-35)-INDUCED NEUROTOXICITY;
D O I
10.2741/4304
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Amyloid-beta peptide (Abeta) is believed to be a central player in the Alzheimer disease (AD) pathogenesis. However, its mechanisms of toxicity to the central nervous system are unknown. To explore this area, investigators have recently focused on Abeta-induced cellular dysfunction. Extensive research has been conducted to investigate Abeta monomers and oligomers, and these multiple facets have provided a wealth of data from specific models. Abeta appears to be accumulated in neuronal mitochondria and mediates mitochondrial toxicity. Mitochondrial dysfunction became a hallmark of Abeta-induced neuronal toxicity. Mitochondria are currently considered as primary targets in the pathobiology of neurodegeneration. This review provides an overview of the Abeta toxicity to isolated mitochondria, mitochondria in different tissues and cells in vitro and in vivo. Full texts and abstracts from all 530 biomedical articles listed in PubMed and published before January 2014 were analysed. The mechanisms underlying the interaction between Abeta and mitochondrial membranes and resulting mitochondrial dysfunction are most disputed issues. Understanding and discussing this interaction is essential to evaluating Abeta effects on various intracellular metabolic processes.
引用
收藏
页码:173 / 197
页数:25
相关论文
共 50 条
  • [1] Fosgonimeton attenuates amyloid-beta toxicity in preclinical models of Alzheimer's disease
    Reda, Sherif M.
    Setti, Sharay E.
    Berthiaume, Andree-Anne
    Wu, Wei
    Taylor, Robert W.
    Johnston, Jewel L.
    Stein, Liana R.
    Moebius, Hans J.
    Church, Kevin J.
    NEUROTHERAPEUTICS, 2024, 21 (04)
  • [2] Presenilins, amyloid-beta and Alzheimer's disease
    Lamb, BT
    NATURE MEDICINE, 1997, 3 (01) : 28 - 29
  • [3] Amyloid-beta and Alzheimer's disease: the role of neprilysin-2 in amyloid-beta clearance
    Marr, Robert A.
    Hafez, Daniel M.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [4] Amyloid-beta antibody treatment in Alzheimer's disease
    Stoegmann, Elisabeth
    Schmidt, Reinhold
    WIENER KLINISCHE WOCHENSCHRIFT, 2024,
  • [5] Amyloid-Beta: A Crucial Factor in Alzheimer's Disease
    Sadigh-Eteghad, Saeed
    Sabermarouf, Babak
    Majdi, Alireza
    Talebi, Mahnaz
    Farhoudi, Mehdi
    Mahmoudi, Javad
    MEDICAL PRINCIPLES AND PRACTICE, 2015, 24 (01) : 1 - 10
  • [6] Alzheimer's disease - The ins and outs of amyloid-beta
    Beyreuther, K
    Masters, CL
    NATURE, 1997, 389 (6652) : 677 - 678
  • [7] Amyloid-Beta Solubility in the Treatment of Alzheimer's Disease
    Murphy, M. Paul
    NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (04): : 391 - 392
  • [8] Chylomicron amyloid-beta in the aetiology of Alzheimer's disease
    Takechi, R.
    Galloway, S.
    Pallebage-Gamarallage, M. M. S.
    Mamo, J. C. L.
    ATHEROSCLEROSIS SUPPLEMENTS, 2008, 9 (02) : 19 - 25
  • [9] Editorial on,"Amyloid-beta clearance in Alzheimer's disease"
    Marr, Robert A.
    FRONTIERS IN AGING NEUROSCIENCE, 2014, 6
  • [10] Plasma amyloid-beta and serum amyloid-beta auto-antibody levels in patients with Alzheimer's disease
    Zhou, L.
    Chu, L. W.
    Kwan, J. S. C.
    Lam, K. S. L.
    Cheng, O. Y.
    Chan, K. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2012, 19 : 98 - 98